Literature DB >> 23934631

Volume-to-creatinine clearance ratio in patients undergoing coronary angiography with or without percutaneous coronary intervention: implications of varying definitions of contrast-induced nephropathy.

Davide Capodanno1, Margherita Ministeri, Silvia Cumbo, Veronica Dalessandro, Corrado Tamburino.   

Abstract

OBJECTIVES: Whether predicting the risk of early serum creatinine rise using the ratio of the volume of contrast media administered to the estimated creatinine clearance (V/CrCl) is applicable to the broader definition of contrast-induced nephropathy (CIN) (≥0.5 mg/dL absolute and/or 25% relative increase from baseline serum creatinine) is unknown.
BACKGROUND: A V/CrCl ≥4 has been proven to predict the risk of ≥0.5 mg/dL postprocedural absolute rise in serum creatinine.
METHODS: A total of 722 patients undergoing coronary angiography ± percutaneous coronary intervention (PCI) between March 2011 and October 2011 with paired serum creatinine determinations at preprocedure and within 72-hr postprocedure were analyzed. The V/CrCl ratio was calculated by dividing the volume of contrast received by the patient's creatinine clearance. CIN using different definitions was termed as CINnarrow (rise in serum creatinine ≥0.5 mg/dL) and CINbroad (rise in serum creatinine ≥0.5 mg/dL and/or ≥25% increase in baseline serum creatinine).
RESULTS: The mean age was 66 ± 11 years and the mean baseline serum creatinine was 1.1 ± 0.8 mg/dL. Patients with V/CrCl ≥4 were significantly older and more frequently underwent ad hoc PCI compared with those with V/CrCl <4. CINnarrow and CINbroad were observed in 13 versus 3% (P < 0.001) and 23 versus 11% (P < 0.001) of patients with or without V/CrCl ≥4, respectively. After statistical adjustment, a V/CrCl ratio ≥4 remained significantly associated with the risk of both CINnarrow [adjusted OR 3.5, 95% confidence intervals (95% CI) 1.7-7.3; P < 0.001] and CINbroad (adjusted OR 2.5, 95% 1.6-3.9; P < 0.001).
CONCLUSIONS: A volume-to-creatinine clearance ratio ≥4 significantly predicts the risk of early postprocedural rise in serum creatinine regardless of the CIN definition adopted.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  CIN; contrast; contrast-induced nephropathy; creatinine clearance

Mesh:

Substances:

Year:  2013        PMID: 23934631     DOI: 10.1002/ccd.25153

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  4 in total

1.  Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention: the MOZART (Minimizing cOntrast utiliZation With IVUS Guidance in coRonary angioplasTy) randomized controlled trial.

Authors:  José Mariani; Cristiano Guedes; Paulo Soares; Silvio Zalc; Carlos M Campos; Augusto C Lopes; André G Spadaro; Marco A Perin; Antonio Esteves Filho; Celso K Takimura; Expedito Ribeiro; Roberto Kalil-Filho; Elazer R Edelman; Patrick W Serruys; Pedro A Lemos
Journal:  JACC Cardiovasc Interv       Date:  2014-10-15       Impact factor: 11.195

2.  Patient-centered contrast thresholds to reduce acute kidney injury in high-risk patients undergoing percutaneous coronary intervention.

Authors:  Ali O Malik; Amit Amin; Kevin Kennedy; Mohammed Qintar; Ali Shafiq; Roxana Mehran; John A Spertus
Journal:  Am Heart J       Date:  2021-01-25       Impact factor: 4.749

3.  Safe contrast volumes for preventing contrast-induced nephropathy in elderly patients with relatively normal renal function during percutaneous coronary intervention.

Authors:  Yong Liu; Yuan-Hui Liu; Ji-Yan Chen; Ning Tan; Ying-Ling Zhou; Chong-Yang Duan; Dan-Qing Yu; Nian-Jin Xie; Hua-Long Li; Ping-Yan Chen
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

4.  Predictors of contrast induced nephropathy and the applicability of the Mehran risk score in high risk patients undergoing coronary angioplasty-A study from a tertiary care center in South India.

Authors:  Sanjai Pattu Valappil; Sivaprasad Kunjukrishnapillai; Mathew Iype; Alummoottil George Koshy; Sunitha Viswanathan; Prabha Nini Gupta; Radhakrishnan Vellikatu Velayudhan; Faeez Mohamad Ali
Journal:  Indian Heart J       Date:  2017-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.